Table 2

Patient demographics and clinical status at baseline

Patient demographics
Age, range, y (M ± SD) 17-86 (57.2 ± 14.5) 
Sex, %  
    Male 55.0 
    Female 45.0 
Race, %  
    White 96.4 
    Non-white 3.6 
Secondary school or higher education, % 55.5 
Living at home alone, % 19.5 
History of CML and treatment  
    Years since CML diagnosis, range, y (M ± SD) 0-29 (4.7 ± 4.4) 
    Symptomatic at diagnosis, % 45.1 
Prior CML treatments and outcome, %  
    Interferon 64.2 
        Failure 28.0 
        Not tolerated 59.0 
        Success but relapse* 13.0 
    Hydroxycarbamide 77.1 
        Failure 40.3 
        Not tolerated 32.3 
        Success but relapse 27.4 
    Transplantation 1.8 
        Failure 0.0 
        Not tolerated 0.0 
        Success but relapse 100.0 
Current CML status  
Disease status, %  
    Primary 93.3 
    Relapse 6.7 
Disease phase  
    Chronic phase 98.2 
    Accelerated phase 1.8 
    Blast crisis 0.0 
Current disease parameters  
    Too early to judge 11.1 
    Available (see Parameters, below) 88.9 
Parameters (if available)  
    Hematologic response  
        Complete 87.0 
        No evidence of leukemia 4.1 
        Return to chronic phase 0.0 
        Not documented 8.9 
    Cytogenetic response 65.1 
        Complete  
        Major 5.3 
        Partial 5.9 
        Not documented 23.7 
    Molecular response  
        ≥ 3 log 47.9 
        ≥ 2 log 13.6 
        Not documented 38.5 
Imatinib treatment, range, mo (M ± SD) 1.0-72.8 (32.9 ± 19.8) 
    Months on imatinib therapy at baseline 100-800 (395.2 ± 77.9) 
    Starting dose, mg/day 100-800 (429.0 ± 106.2) 
    Baseline dose, mg/day 100-800 (420.1 ± 120.0) 
    Follow-up dose, mg/day 100-800 (420.1 ± 120.0) 
Number of patients in whom imatinib treatment changed between baseline and follow-up  
    Imatinib dose change 7 
        100 mg/day 1 
        300 mg/day 2 
        400 mg/day 3 
        600 mg/day 1 
        Change because of intolerance 6 
        Change because of suboptimal response 1 
    Imatinib discontinued 3 
        Intolerance 1 
        Progressive disease 2 
Patient-reported variables, range (M ± SD)  
    Functional status / quality of life (scale of 8-42) 14-42 (31.5 ± 6.5) 
    Quality of chronic care (scale of 1-5) 1-5 (2.8 ± 0.9) 
    Long-term medication behavior self-efficacy (scale of 1-5) 1-5 (4.7 ± 0.5) 
    Knowledge of disease and treatment (scale of 0-100) 0-100 (71.9 ± 20.3) 
Comorbidities, % Past Current 
    Cardiac 11.8 12.4 
    Vascular 7.1 4.1 
    Pulmonary 8.3 4.1 
    Renal 3.0 1.2 
    Hepatic 1.8 1.2 
    Neurologic 6.5 3.0 
    Endocrine/metabolic 7.7 10.7 
    Muscular 2.4 0.6 
    Skeletal 18.9 8.9 
    Skin/connective tissue 6.5 1.2 
    Gastrointestinal 26.0 4.7 
    Genitourinary 10.1 1.8 
    Hematologic (except CML) 3.0 0.0 
Concomitant medications, %  
    Paracetamol 9.5  
Medication burden on typical day Range Q1 Median Q3 
    No. drugs taken per day 1-11 1 2 4 
    No. times per day drugs are taken 1-5 1 2 3 
    No. medication units taken per day 1-18 3 4 6 
Patient demographics
Age, range, y (M ± SD) 17-86 (57.2 ± 14.5) 
Sex, %  
    Male 55.0 
    Female 45.0 
Race, %  
    White 96.4 
    Non-white 3.6 
Secondary school or higher education, % 55.5 
Living at home alone, % 19.5 
History of CML and treatment  
    Years since CML diagnosis, range, y (M ± SD) 0-29 (4.7 ± 4.4) 
    Symptomatic at diagnosis, % 45.1 
Prior CML treatments and outcome, %  
    Interferon 64.2 
        Failure 28.0 
        Not tolerated 59.0 
        Success but relapse* 13.0 
    Hydroxycarbamide 77.1 
        Failure 40.3 
        Not tolerated 32.3 
        Success but relapse 27.4 
    Transplantation 1.8 
        Failure 0.0 
        Not tolerated 0.0 
        Success but relapse 100.0 
Current CML status  
Disease status, %  
    Primary 93.3 
    Relapse 6.7 
Disease phase  
    Chronic phase 98.2 
    Accelerated phase 1.8 
    Blast crisis 0.0 
Current disease parameters  
    Too early to judge 11.1 
    Available (see Parameters, below) 88.9 
Parameters (if available)  
    Hematologic response  
        Complete 87.0 
        No evidence of leukemia 4.1 
        Return to chronic phase 0.0 
        Not documented 8.9 
    Cytogenetic response 65.1 
        Complete  
        Major 5.3 
        Partial 5.9 
        Not documented 23.7 
    Molecular response  
        ≥ 3 log 47.9 
        ≥ 2 log 13.6 
        Not documented 38.5 
Imatinib treatment, range, mo (M ± SD) 1.0-72.8 (32.9 ± 19.8) 
    Months on imatinib therapy at baseline 100-800 (395.2 ± 77.9) 
    Starting dose, mg/day 100-800 (429.0 ± 106.2) 
    Baseline dose, mg/day 100-800 (420.1 ± 120.0) 
    Follow-up dose, mg/day 100-800 (420.1 ± 120.0) 
Number of patients in whom imatinib treatment changed between baseline and follow-up  
    Imatinib dose change 7 
        100 mg/day 1 
        300 mg/day 2 
        400 mg/day 3 
        600 mg/day 1 
        Change because of intolerance 6 
        Change because of suboptimal response 1 
    Imatinib discontinued 3 
        Intolerance 1 
        Progressive disease 2 
Patient-reported variables, range (M ± SD)  
    Functional status / quality of life (scale of 8-42) 14-42 (31.5 ± 6.5) 
    Quality of chronic care (scale of 1-5) 1-5 (2.8 ± 0.9) 
    Long-term medication behavior self-efficacy (scale of 1-5) 1-5 (4.7 ± 0.5) 
    Knowledge of disease and treatment (scale of 0-100) 0-100 (71.9 ± 20.3) 
Comorbidities, % Past Current 
    Cardiac 11.8 12.4 
    Vascular 7.1 4.1 
    Pulmonary 8.3 4.1 
    Renal 3.0 1.2 
    Hepatic 1.8 1.2 
    Neurologic 6.5 3.0 
    Endocrine/metabolic 7.7 10.7 
    Muscular 2.4 0.6 
    Skeletal 18.9 8.9 
    Skin/connective tissue 6.5 1.2 
    Gastrointestinal 26.0 4.7 
    Genitourinary 10.1 1.8 
    Hematologic (except CML) 3.0 0.0 
Concomitant medications, %  
    Paracetamol 9.5  
Medication burden on typical day Range Q1 Median Q3 
    No. drugs taken per day 1-11 1 2 4 
    No. times per day drugs are taken 1-5 1 2 3 
    No. medication units taken per day 1-18 3 4 6 

M indicates mean; SD, standard deviation; Q1, 25th percentile; Median, 50th percentile; and Q3, 75th percentile.

*

Relapse = loss of response.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal